Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study-Reference-Cited by-同舟云学术

Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study

Published:2016-03-31 Issue:8 Volume:114 Page:863-871
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Janni W,Harbeck N,Rack B,Augustin D,Jueckstock J,Wischnik A,Annecke K,Scholz C,Huober J,Zwingers T,Friedl T W P,Kiechle M

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc201682.pdf

Reference28 articles.

1. Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Masuda H, Nomura Y, Sakai K, Sugimachi K, Tominaga T, Uchino J, Yoshida M, Haybittle JL, Davies C, Harvey VJ, Holdaway TM, Kay RG, Mason BH, Forbes JF, Wilcken N, Gnant M, Jakesz R, Ploner M, Yosef HMA, Focan C, Lobelle JP, Peek U, Oates GD, Powell J, Durand M, Mauriac L, Di Leo A, Dolci S, Piccart MJ, Masood MB, Parker D, Price JJ, PSGJ Hupperets, Jackson S, Ragaz J, Berry D, Broadwater G, Cirrincione C, Muss H, Norton L, Weiss RB, Abu-Zahra HT, Portnoj SM, Baum M, Cuzick J, Houghton J, Riley D, Gordon NH, Davis HL, Beatrice A, Mihura J, Naja A, Lehingue Y, Romestaing P, Dubois JB, Delozier T, Mace-Lesec’h J, Rambert P, Andrysek O, Barkmanova J, Owen JR, Meier P, Howell A, Ribeiro GC, Swindell R, Alison R, Boreham J, Clarke M, Collins R, Darby S, Elphinstone P, Evans V, Godwin J, Gray R, Harwood C, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Mead G, Peto R, Wang Y, Albano J, de Oliveira CF, Gervasio H, Gordilho J, Johansen H, Mouridsen HT, Gelman RS, Harris JR, Henderson IC, Shapiro CL, Andersen KW, Axelsson CK, Blichert-Toft M, Moller S, Overgaard J, Overgaard M, Rose C, Cartensen B, Palshof T, Trampisch HJ, Dalesio O, de Vries EGE, Rodenhuis S, van Tinteren H, Comis RL, Davidson NE, Robert N, Sledge G, Tormey DC, Wood W, Cameron D, Chetty U, Forrest P, Jack W, Rossbach J, Klijn JGM, Treurniet-Donker AD, van Putten WLJ, Costa A, Veronesi U, Bartelink H, Duchateau L, Legrand C, Sylvester R, van der Hage JA, van de Velde CJH, Cunningham MP, Catalano R, Creech RH, Bonneterre J, Fargeot P, Fumoleau P, Kerbrat P, Namer M, Jonat W, Kaufmann M, Schumacher M, von Minckwitz G, Bastert G, Rauschecker H, Sauer R, Sauerbrei W, Schauer A, de Schryver A, Vakaet L, Belfiglio M, Nicolucci A, Pellegrini F, Sacco M, Valentini M, McArdle CS, Smith DC, Galligioni E, Boccardo F, Rubagotti A, Dent DM, Gudgeon CA, Hacking A, Erazo A, Medina JY, Izuo M, Morishita Y, Takei H, Fentiman IS, Hayward JL, Rubens RD, Skilton D, Graeff H, Janicke F, Meisner C, Scheurlen H, von Fournier D, Dafni U, Fountzilas G, Klefstrom P, Blomqvist C, Saarto T, Margreiter R, Asselain B, Salmon RJ, Vilcoq JR, Arriagada R, Hill C, Laplanche A, Le MG, Spielmann M, Bruzzi P, Montanaro E, Rosso R, Sertoli MR, Venturini M, Amadori D, Benraadt J, Kooi M, van de Velde AO, van Dongen JA, Vermorken JB, Castiglione M, Cavalli F, Coates A, Collins J, Gelber RD, Goldhirsch A, Lindtner J, Price KN, Rudenstam CM, Senn HJ, Bliss JM, Chilvers CED, Coombes RC, Hall E, Marty M, Borovik R, Brufman G, Hayat H, Robinson E, Wigler N, Bonadonna G, Camerini T, De Palo G, Del Vecchio M, Formelli F, Valagussa P, Martoni A, Pannuti F, Cocconi G, Colozza A, Camisa R, Aogi K, Takashima S, Ikeda T, Inokuchi K, Sawa K, Sonoo H, Korzeniowski S, Skolyszewski J, Ogawa M, Yamashita J, Bonte J Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687–1717.

2. Albert JM, Buzdar AU, Guzman R, Allen PK, Strom Ea, Perkins GH, Woodward Wa, Hoffman KE, Tereffe W, Hunt KK, Buchholz Ta, Oh JL (2011) Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) vs paclitaxel and FAC (TFAC) in patients with operable breast cancer: Impact of taxane chemotherapy on locoregional control. Breast Cancer Res Treat 128: 421–427.

3. Burnell M, Levine MN, Chapman JW, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, Brien PO, Shepherd LE (2010) Cyclophosphamide, epirubicin, and fluorouracil vs dose-dense epirubicin and cyclophosphamide followed by paclitaxel vs doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol 28: 77–82.

4. Clarke M (2006) Meta-analyses of adjuvant therapies for women with early breast cancer: The Early Breast Cancer Trialists’ Collaborative Group overview. Ann Oncol 17: 59–62.

5. Coudert B, Asselain B, Campone M, Spielmann M, Machiels J-P, Pénault-Llorca F, Serin D, Lévy C, Romieu G, Canon J-L, Orfeuvre H, Piot G, Petit T, Jerusalem G, Audhuy B, Veyret C, Beauduin M, Eymard J-C, Martin A-L, Roché H (2012) Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial. Oncologist 17: 900–909.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial;Clinical Breast Cancer;2020-12

2. Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review;Cancer Medicine;2020-05-26

3. Biomimetic nanovesicles made from iPS cell-derived mesenchymal stem cells for targeted therapy of triple-negative breast cancer;Nanomedicine: Nanotechnology, Biology and Medicine;2020-02

4. Taxanes for adjuvant treatment of early breast cancer;Cochrane Database of Systematic Reviews;2019-09-02

5. Adjuvant Effect of Molecular Iodine in Conventional Chemotherapy for Breast Cancer. Randomized Pilot Study;Nutrients;2019-07-17